ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2001

Kaiser Permanent Pyramid In Patients With Gout: The Most Severe Gout Is Associated To The Most Complex Patients

Fernando Perez-Ruiz1,2, Ana M. Herrero-Beites1,3 and Amaya Martinez-Galarza4,5, 1BioCruces Health Research Institute, Baracaldo, Spain, 2Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, 3Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain, 4Clinical Investigation Unit, Hospital Universitario Cruces, Baracaldo, Spain, 5BioCruces Health Institute, Baracaldo, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: gout, management and severity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies II

Session Type: Abstract Submissions (ACR)

Background/Purpose: gout is well known to be associated with comorbid conditions; the Kaiser Permanente Pyramid (KPP) identify high risk people (two higher strata) in the population, in order to support them in an individualized and multidisciplinary management, respectively, to avoid admissions. This study intends to evaluate whether severity of gout is also associated with higher KPP.

Methods: prospective cohort of follow-up of gout patients in whom KPP distribution was endorsed by the health system in the patientsx electronic file from Sept 2012. Comorbid conditions known to be cardiovascular risk factors (hypertension, glomerular filtration, diabetes, hyperlipidemia, vascular events), were recorded in the patientsx record file at baseline. In addition, evaluation of the severity of gout according to the number of flares (previous year), joint distribution, presence of subcutaneous tophi, and X-ray abnormalities related to gout, along with acute kidney injury related to the previous use of NSAIDs were also recorded at baseline evaluation.

Results: 256 patients, 92.2% men, 77% crystal and 11% hs-ultrasound based diagnosis, have been evaluated using the KPP.  KPP higher strata included 132 (51.5%) of all the patients: 72 (28.1%) considered as high risk /disease care patients and 60 (23.4%) as very complex/case management patients. Comorbidities associated with gout were much more prevalent in the two higher strata of KPP (Table), but also showed that polyarticular distribution, presence of tophi, and X-ray abnormalities were more prevalent in these patients. Interestingly, previous acute kidney injury attributed to NSAIDs was ten-fold in these high-risk patients compared to low-risk patients.

KPP

Age

(yr)

Women

(%)

Onset

(yr)

FGR

(ml/min)

HT

(%)

DM

(%)

HLP

(%)

VE

(%)

Flares

(yr)

Poly

(%)

Tophi

(%)

X-ray

(%)

AKI

(%)

0-1

N= 124

55±11

4.0

8.4±8.4

53±26

36

7

55

11

4±4

37

35

46

1.6

2-3

N= 132

67±11**

11.4**

7.3±7.1

89±24**

73

30**

55

56**

4±6

58**

46*

70**

15.9**

Conclusion: patients with the highest clinical complexity according to Kaiser Permanente Pyramid also showed the most severe gout, indicating that these complex-severe patients could well deserve specific rheumatologic or even multidisciplinary management. 


Disclosure:

F. Perez-Ruiz,

Menarini International,

5,

SOBI,

5,

AstraZeneca,

5,

Menarini,

8;

A. M. Herrero-Beites,
None;

A. Martinez-Galarza,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kaiser-permanent-pyramid-in-patients-with-gout-the-most-severe-gout-is-associated-to-the-most-complex-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology